Prime Minister Andy Burnham, whose father died from Alzheimer’s last month, said he knew how it felt to lose a loved one to dementia, and had seen first-hand the devastating impact of the disease on families.
“That’s why I’m proud to see this trial being launched in the UK, so that cutting-edge treatments can reach patients here as soon as possible,” he said.
The AD-SMART study is what’s known as a multi-arm, multi-stage platform trial where several treatments are tested simultaneously, with the results compared with one group of participants taking a placebo or dummy.
This means those involved have a higher likelihood of getting an active treatment than in a traditional trial.
If any drug isn’t showing benefit it can be dropped quickly and a new treatment added in its place – the approach has been used successfully in cancer and motor neurone disease.
The two initial drugs being tested are metformin, used to treat type 2 diabetes, and atomoxetine, for ADHD, which were selected by an international panel of experts.
Both drugs may help reduce brain inflammation, which is a driver of neurodegeneration, said chief investigator Prof Paresh Malhotra, group leader at the UK Dementia Research Institute Centre for Care Research & Technology at Imperial College London.
“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer – sometimes taking a decade or more before we know if we’ve found something that works,” he told the BBC.
“We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer’s disease.”
